AI assistant
Accretion Nutraveda Limited — Earnings Release 2026
May 15, 2026
60615_rns_2026-05-15_7f9e68d0-54f4-4d52-9b2a-05c862093b27.pdf
Earnings Release
Open in viewerOpens in your device viewer
Accretion® Nutraveda Limited
Formerly known as Accretion Nutraveda Private Limited
Date: 15th May, 2026
To,
Corporate Relations Department
BSE Limited
25th Floor, P J Towers,
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: 544694
Dear Sir/ Madam,
Subject: Media Release for the year ended on 31st March, 2026
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the media release of our Company for the year ended on 31st March, 2026, the content of which is self-explanatory.
You are requested to kindly take on your record.
Thanking You.
Yours truly,
For Accretion Nutraveda Limited
[Formerly Known as Accretion Nutraveda Private Limited]
PAYAL
HARESHBHAI
KOTADIYA
Digitally signed by
PAYAL HARESHBHAI
KOTADIYA
Date: 2026.05.15
18:50:43 +05'30'
Payal Kotadiya
Company Secretary and Compliance Officer
27, Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta-Sanand, Ahmedabad 382 213, Gujarat, INDIA
Contact: 079-45906329 Email: [email protected] Website: www.accretionnutraveda.com CIN: L24290GJ2021PLC121216
AccretiOn Nutraveda Limited Formerly known as Accretion Nutraveda Private Limited
Media Release
Company Delivers Robust Performance in H2 FY26: Revenue up 80.09% YoY and EBITDA up 42.64%
Growth Driven by Strong Demand, Operational Expansion and Expanding Market Presence
Ahmedabad, 15th May, 2026: Accretion Nutraveda Limited (BSE SME Exchange: ANL), a fast-growing nutraceutical and ayurvedic products and contract development and manufacturing organization (CDMO) services, company listed on the BSE SME Platform, announced its Audited Financial Results for the year ended 31st March, 2026.
Key Financial Highlights (Rs. In Crore):
| Particulars | H2 FY26 | H2 FY25 | YoY % | H1 FY26 | FY26 | FY25 | YoY % |
|---|---|---|---|---|---|---|---|
| Net Revenue | 19.54 | 10.85 | 80.09% | 14.06 | 33.6 | 16 | 110.00% |
| EBIDTA | 3.68 | 2.58 | 42.64% | 3.33 | 7.01 | 3.73 | 87.94% |
| EBIDTA Margin % | 18.81% | 23.76% | (495 Bps) | 23.69% | 20.85% | 23.31% | (246 Bps) |
| PAT | 2.69 | 1.72 | 56.40% | 2.38 | 5.07 | 2.5 | 102.80% |
| PAT Margin % | 13.76% | 15.87% | (211 Bps) | 16.92 | 15.08% | 15.63% | (55 Bps) |
Financial Results Highlights for the Half year ended 31st March 2026:
- Net Revenue in H2 FY26 stood at Rs. 19.54 crore as against Rs. 10.85 crore in H2 FY25, registering a strong YoY growth of 80.09%. The growth was driven by higher demand across nutraceutical and ayurvedic products, improved the product mix, stronger contribution from CDMO operations, and improved market penetration across key regions.
- EBITDA stood at Rs. 3.68 crore in H2 FY26 as against Rs. 2.58 crore in H2 FY25, reflecting a YoY growth of 42.64%, with EBITDA Margin at 18.81% in H2 FY26. The growth was driven by higher business volumes and improved operational efficiencies, though partially offset by increased raw material prices, IPO-related expenses, and higher manpower costs linked to team expansion for dossier preparation, regulatory and business development activities undertaken to support future growth.
- Profit After Tax increased by 56.40% YoY to Rs. 2.69 crore in H2 FY26, with a PAT Margin of 13.76%. The improvement in profitability was driven by strong revenue growth, improved operating leverage, and efficient cost management across business operations.
AccretiOn Nutraveda Limited Formerly known as Accretion Nutraveda Private Limited
Financial Results Highlights for the Year ended 31st March 2026:
- Net Revenue for FY26 stood at Rs. 33.60 crore as compared to Rs. 16.00 crore in FY25, registering an exceptional growth of 110.00% YoY. The growth was driven by strong demand across nutraceutical and ayurvedic products, expansion of customer base, improved product mix, increased contribution from CDMO services, and strengthening of the team through experienced technocrats and improved documentation processes.
- EBITDA for FY26 stood at Rs. 7.01 crore as against Rs. 3.73 crore in FY25, reflecting a strong YoY growth of 87.94% with EBITDA Margin at 20.85% in FY26. The growth was driven by robust revenue performance, improved operational efficiency, better cost optimization, and higher contribution from core business segments. Margin performance during the year was impacted by higher input costs and initial scale-up expenses incurred towards business expansion, team strengthening, and operational enhancement initiatives.
- Profit After Tax (PAT) for FY26 Increased significantly by 102.80% YoY to Rs. 5.07 crore compared to Rs. 2.50 crore in FY25. PAT Margin stood at 15.08%
Management Comment:
Commenting on the Company's performance, Mr. Mayur Popatlal Sojitra, Managing Director of Accretion Nutraveda Limited said:
"We are pleased to report a strong financial and operational performance for FY26, marked by robust revenue growth and significant improvement in profitability. During the year, the Company achieved total revenue of ₹33.60 crore, reflecting a strong growth of 110.00% YoY, while Profit After Tax increased by 102.80% YoY to ₹5.07 crore. The growth was primarily driven by increasing demand across our nutraceutical and ayurvedic product portfolio, expansion in customer base, and continued growth in our CDMO.
FY26 has been an important milestone year for Accretion Nutraveda Limited with the successful completion of its Initial Public Offering (IPO) and listing on the BSE SME Platform at an almost 50% premium. The IPO has strengthened the Company's financial position and will support future expansion plans, including manufacturing capacity enhancement, automation initiatives, and operational improvements.
Accretion® Nutraveda Limited Formerly known as Accretion Nutraveda Private Limited
During the year, we continued to focus on strengthening our manufacturing capabilities, expanding product offerings, and improving operational efficiencies. We witnessed healthy demand momentum across our existing markets, supported by strong customer relationships, repeat business orders, and growing acceptance of nutraceutical and ayurvedic products among consumers.
Our export-led strategy continues to be a key growth driver, supported by ongoing capacity expansion initiatives funded through IPO proceeds. These efforts are aimed at expanding into new geographies while further strengthening our presence in existing international markets. With multiple products currently under registration and various market approvals underway, we are well positioned to enhance our global footprint, deepen customer relationships, and unlock new growth opportunities across the nutraceutical and ayurvedic product segments.
Looking ahead, we remain focused on achieving sustainable long-term growth through continued investments in manufacturing infrastructure, product innovation, quality standards, and strengthening our presence across both domestic and international markets. We are confident that our customer-centric approach, strong focus on quality-driven operations, and well-defined growth strategy will continue to drive business excellence and create long-term value for all stakeholders.
As we continue our journey forward, we remain committed to our motto, “Accretion – Growing Together,” reflecting our belief in creating sustainable growth and shared success for everyone associated with the Company.
We sincerely thank all our stakeholders, shareholders, clients, vendors, business partners, and employees for their continued trust, confidence, and support towards Accretion Nutraveda Limited.
Company Overview
Accretion Nutraveda Limited, headquartered in Ahmedabad, Gujarat, India, is a fast-growing nutraceutical and ayurvedic products company listed on the BSE SME Exchange since February 04, 2026. The Company is engaged in the development, manufacturing, marketing, and distribution of a wide range of nutraceutical, herbal, wellness, and ayurvedic products. Operating from its manufacturing facility at Xcelon Industrial Park, Sanand, Ahmedabad, Gujarat, India, the Company also provides contract development and manufacturing organization (CDMO) services, private labeling, and third-party manufacturing solutions for domestic and international clients. The
Accretion® Nutraveda Limited Formerly known as Accretion Nutraveda Private Limited
Company focuses on delivering quality-driven healthcare and wellness products supported by strong manufacturing capabilities, operational excellence, and customer-centric solutions.
Our Company operates from a well-equipped manufacturing facility adhering to stringent quality and compliance standards. The facility is certified with FSSAI License, ISO 9001:2015, ISO 45001:2018, FSSC 22000, WHO-GMP, Halal Certification, and GMP Certification reflecting the Company's strong commitment towards quality manufacturing, food safety, operational excellence, and regulatory compliance. The Company is led by an experienced Board of Directors and a professional management team having extensive experience in the nutraceutical and ayurvedic industry.
For more details please visit: www.accretionnutraveda.com
For further information please contact:
Payal Kotadiya
Company Secretary & Compliance Officer
Accretion Nutraveda Limited
E-mail: [email protected]
Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.